美股异动丨Moderna盘前跌3.5% 因美国官员反对缩减疫苗试验投资

Group 1 - The core viewpoint of the article is that Moderna's CEO announced the company will not invest in new late-stage vaccine trials due to increasing opposition from U.S. officials regarding vaccine uptake, which significantly reduces the potential market size [1] - The CEO, Stéphane Bancel, stated that without access to the U.S. market, the company cannot achieve a return on investment [1] - Regulatory delays and lack of support from U.S. health officials have been highlighted as key factors contributing to the shrinking market opportunity for Moderna [1] Group 2 - As of January 22, Moderna's stock closed at $51.870, with a pre-market drop of 3.9% to $49.840 on January 23 [2] - The stock's highest price in the last 52 weeks was $55.200, while the lowest was $22.280 [2] - The company's total market capitalization is approximately $20.265 billion, with a trading volume of 34.2435 million shares [2]